February 22, 2021
Chugai Pharmaceutical said on February 19 that it has obtained exclusive rights to develop and commercialize Atea Pharmaceuticals’ investigational COVID-19 treatment AT-527 in Japan under a pact sealed with Roche, the US biotech’s global partner for the compound. Originated by...read more